左炔诺孕酮宫内节育器与全身孕激素治疗肥胖女性复杂非典型增生的比较
这项单机构回顾性研究纳入2003至2018年接受孕激素治疗的245例复杂非典型增生女性,比较左炔诺孕酮宫内节育器(69例)与全身孕激素治疗(176例)的疗效。结果显示,宫内节育器组完全缓解率更高(78.7% vs 46.7%;调整风险比3.32,95%CI 2.39-4.62),进展为癌的风险更低(4.5% vs 15.7%;调整风险比0.28,95%CI 0.11-0.73),尤其在III级肥胖女性中相对获益更大。
要点
- 左炔诺孕酮宫内节育器组完全缓解率78.7%,全身治疗组46.7%,调整风险比3.32。
- 宫内节育器组进展为癌风险4.5%,全身治疗组15.7%,调整风险比0.28。
- III级肥胖女性从宫内节育器治疗中获得的完全缓解相对获益更高(调整风险比4.72)。
核心结论
- 对于选择非手术治疗的复杂非典型增生女性,左炔诺孕酮宫内节育器局部治疗可能比全身孕激素治疗更有效,尤其在病态肥胖女性中。
研究设计与样本
- 单机构回顾性研究,纳入2003至2018年接受孕激素治疗的245例复杂非典型增生女性,其中左炔诺孕酮宫内节育器组69例,全身治疗组176例。
- 采用倾向评分逆概率治疗加权模型构建加权队列,并进行交互项分析和中断时间序列分析。
主要发现
- 左炔诺孕酮宫内节育器组完全缓解率78.7%,全身治疗组46.7%,调整风险比3.32(95%CI 2.39-4.62)。
- 左炔诺孕酮宫内节育器组进展为癌的比例4.5%,全身治疗组15.7%,调整风险比0.28(95%CI 0.11-0.73)。
- III级肥胖女性完全缓解的调整风险比4.72(95%CI 2.83-7.89),I-II级肥胖为1.83(95%CI 1.09-3.09),非肥胖为1.26(95%CI 0.40-3.95)。
临床怎么用
- 对于有生育要求或手术条件差的复杂非典型增生女性,可优先考虑左炔诺孕酮宫内节育器局部治疗,尤其在病态肥胖患者中。
局限性
- 本研究为单机构回顾性研究,可能存在选择偏倚和未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Though hysterectomy remains the standard treatment for complex atypical hyperplasia, patients who desire fertility or who are poor surgical candidates may opt for progestin therapy. However, the effectiveness of the levonorgestrel-releasing intrauterine device compared to systemic therapy in the treatment of complex atypical hyperplasia has not been well studied. OBJECTIVE: We sought to examine differences in treatment response between local progestin therapy with the levonorgestrel-releasing intrauterine device and systemic progestin therapy in women with complex atypical hyperplasia. METHODS: This single-institution retrospective study examined women with complex atypical hyperplasia who received progestin therapy between 2003 and 2018. Treatment response was assessed by histopathology on subsequent biopsies. Time-dependent analyses of complete response and progression to cancer were performed comparing the levonorgestrel-releasing intrauterine device and systemic therapy. A propensity score inverse probability of treatment weighting model was used to create a weighted cohort that differed based on treatment type but was similar with respect to other characteristics. An interaction-term analysis was performed to examine the impact of body habitus on treatment response, and an interrupted time-series analysis was employed to assess if changes in treatment patterns correlated with outcomes over time. RESULTS: A total of 245 women with complex atypical hyperplasia received progestin therapy (levonorgestrel-releasing intrauterine device n = 69 and systemic therapy n = 176). The mean age and body mass index were 36.9 years and 40.0 kg/m2, respectively. In the patient-level analysis, women who received the levonorgestrel-releasing intrauterine device had higher rates of complete response (78.7% vs 46.7%; adjusted hazard ratio, 3.32; 95% confidence interval, 2.39-4.62) and a lower likelihood of progression to cancer (4.5% vs 15.7%; adjusted hazard ratio, 0.28; 95% confidence interval, 0.11-0.73) compared to those who received systemic therapy. In particular, women with class III obesity derived a higher relative benefit from levonorgestrel-releasing intrauterine device therapy in achieving complete response compared to systemic therapy: class III obesity, adjusted hazard ratio 4.72, 95% confidence interval 2.83-7.89; class I-II obesity, adjusted hazard ratio 1.83, 95% confidence interval 1.09-3.09; and nonobese, adjusted hazard ratio 1.26, 95% confidence interval 0.40-3.95. In the cohort-level analysis, the obesity rate increased during the study period (77.8% to 88.2%, 13.4% relative increase, P = .033) and levonorgestrel-releasing intrauterine device use significantly increased after 2007 (6.3% to 82.7%, 13.2-fold increase, P < .001), both concomitant with a higher proportion of women achieving complete response (32.9% to 81.4%, 2.5-fold increase, P = .005). CONCLUSION: Our study suggests that local therapy with the levonorgestrel-releasing intrauterine device may be more effective than systemic therapy for women with complex atypical hyperplasia who opt for nonsurgical treatment, particularly in morbidly obese women. Shifts in treatment paradigm during the study period toward increased levonorgestrel-releasing intrauterine device use also led to improved complete response rates despite increasing rates of obesity.
引用
- Mandelbaum RS, Ciccone MA, Nusbaum DJ, et al. Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy. Am J Obstet Gynecol. 2020. PMID: 31978437. doi:10.1016/j.ajog.2019.12.273
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。